The corticotropin-releasing hormone network and the hypothalamic-pituitary- adrenal axis: Molecular and cellular mechanisms involved

Neuroendocrinology

Volumn 94, Issue 1, 2011, Pages 12-20

  Bonfiglio, Juan José ^a   Inda, Carolina ^a   Refojo, Damián ^b   Holsboer, Florian ^b   Arzt, Eduardo ^a   Silberstein, Susana ^a  

^a INSTITUTO DE FISIOLOGÍA   (Argentina)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

B Raf; CRH receptor; CRH signaling; HPA axis; MAPK

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ANXIETY; ARTICLE; DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; CENTRAL NERVOUS SYSTEM; CORTICOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MODELS, ANIMAL; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION;

EID: 79960941611     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000328226     Document Type: Article

References (59)

1. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-1397. (Pubitemid 12243637)
2. de Kloet ER, Joels M, Holsboer F: Stress and the brain: From adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475. (Pubitemid 40769171)
3. Smith SM, Vale WW: The role of the hypothalamic- pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 2006; 8: 383-395. (Pubitemid 46110385)
4. Holsboer F, Ising M: Stress hormone regulation: Biological role and translation into therapy. Annu Rev Psychol 2010; 61: 81-109, C101-C111.
5. Hillhouse EW, Grammatopoulos DK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin- releasing hormone receptors: Implications for physiology and pathophysiology. Endocr Rev 2006; 27: 260-286.
6. del Rey A, Besedovsky HO: The cytokine- HPA axis circuit contributes to prevent or moderate autoimmune processes. Z Rheumatol 2000; 59(Suppl 2):II/31-35.
7. Swanson LW, Sawchenko PE, Rivier J, Vale WW: Organization of ovine corticotropinreleasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 1983; 36: 165-186. (Pubitemid 13138041)
8. Bale TL, Vale WW: CRF and CRF receptors: Role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004; 44: 525-557. (Pubitemid 38263852)
9. Korosi A, Baram TZ: The central corticotropin releasing factor system during development and adulthood. Eur J Pharmacol 2008; 583: 204-214.
10. Steckler T, Holsboer F: Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999; 46: 1480-1508.
11. Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick- Gallagher P: Synaptic physiology of central CRH system. Eur J Pharmacol 2008; 583: 215-225.
12. Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002; 2: 23-33.
13. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1-12. (Pubitemid 29044562)
14. Holsboer F: The rationale for corticotropinreleasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214. (Pubitemid 29178663)
15. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093-1102. (Pubitemid 28293127)
16. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19: 162-166. (Pubitemid 28248798)
17. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kuhn R, Reul JM, Holsboer F, Wurst W: Limbic corticotropinreleasing hormone receptor 1 mediates anxiety- related behavior and hormonal adaptation to stress. Nat Neurosci 2003; 6: 1100-1107. (Pubitemid 37186203)
18. Grigoriadis DE: The corticotropin-releasing factor receptor: A novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005; 9: 651-684. (Pubitemid 41131672)
19. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM: Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: New molecular targets. CNS Neurol Disord Drug Targets 2006; 5: 453-479. (Pubitemid 44203356)
20. Holsboer F, Ising M: Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008; 583: 350-357.
21. Markovic D, Grammatopoulos DK: Focus on the splicing of secretin GPCRs transmembrane- domain 7. Trends Biochem Sci 2009; 34: 443-452.
22. Zmijewski MA, Slominski AT: Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol 2010; 57: 1-13.
23. Chen A, Perrin M, Brar B, Li C, Jamieson P, Digruccio M, Lewis K, Vale W: Mouse corticotropin- releasing factor receptor type 2alpha gene: Isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 2005; 19: 441-458. (Pubitemid 40223468)
24. Mikhailova MV, Mayeux PR, Jurkevich A, Kuenzel WJ, Madison F, Periasamy A, Chen Y, Cornett LE: Heterooligomerization between vasotocin and corticotropin-releasing hormone (CRH) receptors augments CRHstimulated 3 ,5β-cyclic adenosine monophosphate production. Mol Endocrinol 2007; 21: 2178-2188. (Pubitemid 47347380)
25. Young SF, Griffante C, Aguilera G: Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors. Cell Mol Neurobiol 2007; 27: 439-461. (Pubitemid 46763890)
26. Dautzenberg FM, Hauger RL: The CRF peptide family and their receptors: Yet more partners discovered. Trends Pharmacol Sci 2002; 23: 71-77. (Pubitemid 34119328)
27. Brar BK, Chen A, Perrin MH, Vale W: Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin- releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 2004; 145: 1718-1729. (Pubitemid 38402380)
28. Lefkowitz RJ, Shenoy SK: Transduction of receptor signals by beta-arrestins. Science 2005; 308: 512-517.
29. Arzt E, Holsboer F: CRF signaling: Molecular specificity for drug targeting in the CNS. Trends Pharmacol Sci 2006; 27: 531-538. (Pubitemid 44374761)
30. Maira M, Martens C, Philips A, Drouin J: Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999; 19: 7549-7557. (Pubitemid 29493418)
31. Maira M, Martens C, Batsche E, Gauthier Y, Drouin J: Dimer-specific potentiation of NGFI-B (Nur77) transcriptional activity by the protein kinase A pathway and AF-1-dependent coactivator recruitment. Mol Cell Biol 2003; 23: 763-776. (Pubitemid 36133496)
32. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, Arzt E: Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: Involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 2002; 16: 1638-1651. (Pubitemid 34746009)
33. Martens C, Bilodeau S, Maira M, Gauthier Y, Drouin J: Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor. Mol Endocrinol 2005; 19: 885-897. (Pubitemid 40397054)
34. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J: Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 2006; 20: 2871-2886. (Pubitemid 44771748)
35. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, Renner U, Stalla GK, Arzt E: Bone morphogenetic protein-4 inhibits corticotroph tumor cells: Involvement in the retinoic acid inhibitory action. Endocrinology 2006; 147: 247-256. (Pubitemid 43004278)
36. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E: Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006; 147: 4438-4444. (Pubitemid 44268395)
37. Tsukamoto N, Otsuka F, Miyoshi T, Yamanaka R, Inagaki K, Yamashita M, Otani H, Takeda M, Suzuki J, Ogura T, Iwasaki Y, Makino H: Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: Involvement of up-regulation of BMP receptor signaling by somatostatin analogs. Endocrinology 2010; 151: 1129-1141.
38. Cibelli G, Corsi P, Diana G, Vitiello F, Thiel G: Corticotropin-releasing factor triggers neurite outgrowth of a catecholaminergic immortalized neuron via cAMP and MAP kinase signalling pathways. Eur J Neurosci 2001; 13: 1339-1348. (Pubitemid 32328488)
39. Teli T, Markovic D, Hewitt ME, Levine MA, Hillhouse EW, Grammatopoulos DK: Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. Cell Signal 2008; 20: 40-49. (Pubitemid 350138368)
40. Grammatopoulos DK, Randeva HS, Levine MA, Katsanou ES, Hillhouse EW: Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: An effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 2000; 14: 2076-2091.
41. Punn A, Levine MA, Grammatopoulos DK: Identification of signaling molecules mediating corticotropin-releasing hormone- R1alpha-mitogen-activated protein kinase (MAPK) interactions: The critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 2006; 20: 3179-3195. (Pubitemid 44833564)
42. Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK: Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: Structural determinants for G protein-coupled receptor kinasemediated phosphorylation and agonistmediated desensitization. Mol Endocrinol 2005; 19: 474-490. (Pubitemid 40223470)
43. Holmes KD, Babwah AV, Dale LB, Poulter MO, Ferguson SS: Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. J Neurochem 2006; 96: 934-949.
44. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin JP, Anisman H, Ferguson SS: CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 2010; 13: 622-629.
45. Thomas GM, Huganir RL: MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004; 5: 173-183. (Pubitemid 38252474)
46. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G: The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311-7316. (Pubitemid 36999520)
47. Stork PJ, Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002; 12: 258-266. (Pubitemid 34634174)
48. Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht E, Peeters PJ: Corticotropin releasing factorinduced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology 2010; 58: 135-144.
49. Refojo D, Echenique C, Muller MB, Reul JM, Deussing JM, Wurst W, Sillaber I, Paez-Pereda M, Holsboer F, Arzt E: Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc Natl Acad Sci USA 2005; 102: 6183-6188. (Pubitemid 40594275)
50. Wiese S, Pei G, Karch C, Troppmair J, Holtmann B, Rapp UR, Sendtner M: Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons. Nat Neurosci 2001; 4: 137-142. (Pubitemid 32125257)
51. Bonfiglio JJ, Maccarrone G, Rewerts C, Holsboer F, Arzt E, Turck CW, Silberstein S: Characterization of the B-Raf interactome in mouse hippocampal neuronal cells. J Proteomics 2010; 74: 186-198.
52. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W: Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992; 130: 3378-3386.
53. Groenink L, Dirks A, Verdouw PM, Schipholt M, Veening JG, van der Gugten J, Olivier B: HPA axis dysregulation in mice overexpressing corticotropin releasing hormone. Biol Psychiatry 2002; 51: 875-881. (Pubitemid 34521935)
54. Lu A, Steiner MA, Whittle N, Vogl AM, Walser SM, Ableitner M, Refojo D, Ekker M, Rubenstein JL, Stalla GK, Singewald N, Holsboer F, Wotjak CT, Wurst W, Deussing JM: Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry 2008; 13: 1028-1042.
55. Kimura M, Muller-Preuss P, Lu A, Wiesner E, Flachskamm C, Wurst W, Holsboer F, Deussing JM: Conditional corticotropinreleasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 2010; 15: 154-165.
56. Refojo D, Holsboer F: CRH signaling. Molecular specificity for drug targeting in the CNS. Ann NY Acad Sci 2009; 1179: 106-119.
57. Silberstein S, Vogl AM, Refojo D, Senin SA, Wurst W, Holsboer F, Deussing JM, Arzt E: Amygdaloid pERK1/2 in corticotropin-releasing hormone overexpressing mice under basal and acute stress conditions. Neuroscience 2009; 159: 610-617.
58. Reyes BA, Valentino RJ, Van Bockstaele EJ: Stress-induced intracellular trafficking of corticotropin-releasing factor receptors in rat locus coeruleus neurons. Endocrinology 2008; 149: 122-130.
59. Waselus M, Nazzaro C, Valentino RJ, Van Bockstaele EJ: Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol Psychiatry 2009; 66: 76-83.